Chennai: Showing the effectiveness of digital therapies (dtx) among patients with acute coronary syndrome (DHW) and post-percutaneous coronary interventions, Lupine Digital Health (LDH), a DTx platform, has published the results of a study in India.
The one-year study aimed to evaluate the efficacy of the LDH digital therapy platform, Lyfe, on cardiovascular events, rehospitalization, medication adherence, vital sign monitoring, and lifestyle changes among cardiac patients. During the 90-day interim analysis, LDH revealed that patients enrolled in the program demonstrated significant improvement, with 90 percent adhering to the recommended regimen of medication, diet, and exercise. 83.3 percent of patients maintained their vital signs within the normal range and there were no readmissions during the first 30 days of enrollment.
The study findings were presented at the India Live 2023 symposium in Chennai. LDH, a wholly owned subsidiary of global pharmaceutical lupine limitedrecently launched its digital therapy platform, Lyfe, which the company says is an evidence-based, holistic cardiac care program that significantly reduces the risk of heart attack and improves the quality of life for cardiac patients.
By emphasizing the use of evidence-based technologies like digital therapy, we are revolutionizing the way we provide healthcare to our patients, Dr. Abhijeet Palshikarinterventional cardiologist, Pune, said: “As an interventional cardiologist, I am happy to see such positive and promising early results from the study, with more than 90 per cent of patients adhering to the medication, diet and exercise regimen recommended by While This is an excellent start, we intend to conduct extensive clinical studies and foster collaborative efforts among all healthcare stakeholders to establish digital therapies in cardiology and unlock their full potential.”
The reported study results suggest that digital therapy programs will play a crucial role in patient care across the technology-driven continuum of cardiology. According to the company, these results show a promising future for remote patient care in cardiology, using the potential of digital health to improve the cardiac health of patients.
While noting that the study results show the efficacy of our evidence-based comprehensive cardiac care program in ensuring high adherence and low rehospitalization of patients, Siddhartha ShrinivasanCEO of Lupine Digital Health, said: “We are excited to share the positive results of India’s first digital therapy study. It is gratifying to see that more than 300 leading cardiologists have already signed up for our Lyfe platform, and we are confident that this number will multiply.”
“We are dedicated to optimizing the patient experience by improving physician-patient collaboration, continuously monitoring vital health signs, increasing patient awareness, and improving adherence to therapy, all of which lead to better outcomes,” Srinivasan concluded.
